<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic intestinal pseudo-obstruction: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic intestinal pseudo-obstruction: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic intestinal pseudo-obstruction: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Camilleri, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence S Friedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3090260906"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pseudo-obstruction is a syndrome characterized by signs and symptoms of a mechanical obstruction of the small or large bowel in the absence of an anatomic lesion that obstructs the flow of intestinal contents. Pseudo-obstruction may be acute or chronic and is characterized by the presence of dilatation of the bowel on imaging. When there is evidence of chronic small intestinal motility disorder in the absence of bowel dilatation, the preferred term is chronic intestinal dysmotility.</p><p>This topic review will discuss the management of chronic intestinal pseudo-obstruction (CIPO). The etiology, clinical manifestations, and diagnosis of CIPO, acute colonic pseudo-obstruction (Ogilvie syndrome), chronic intestinal dysmotility, and slow transit constipation/colon inertia are discussed separately. (See  <a class="medical medical_review" href="/d/html/2639.html" rel="external">"Chronic intestinal pseudo-obstruction: Etiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2531.html" rel="external">"Acute colonic pseudo-obstruction (Ogilvie's syndrome)"</a> and  <a class="medical medical_review" href="/d/html/2637.html" rel="external">"Etiology and evaluation of chronic constipation in adults"</a>.)</p><p class="headingAnchor" id="H1947422878"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>Initial management of chronic intestinal pseudo-obstruction (CIPO) consists of dietary modification and treatment of the underlying disease. In patients with continued symptoms, pharmacologic therapy with prokinetic and antiemetics may be required. Patients should be managed by a multidisciplinary team including a gastroenterologist, nutritionist, and a general, and in some cases a transplant, surgeon with experience in the treatment of CIPO [<a href="#rid1">1,2</a>]. </p><p class="headingAnchor" id="H1238208289"><span class="h2">General measures in all patients</span></p><p class="headingAnchor" id="H4055252694"><span class="h3">Dietary modification</span><span class="headingEndMark"> — </span>Early intervention with nutritional support is important, particularly for those who have had recurrent vomiting or reduced oral intake. Small meals consisting of liquid or homogenized foods are better tolerated than solids. Patients with CIPO frequently require supplemental nutritional support. Hypercaloric liquid formulations should be used in patients with low caloric intake. Enteral nutrition is typically used in patients with a neuropathic disorder and in whom the motility disorder is localized to the stomach and duodenum. <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">Parenteral nutrition</a> may be necessary for patients with severe dysmotility (usually myopathic pseudo-obstruction). (See <a class="local">'Decompression and feeding'</a> below and <a class="local">'Parenteral nutrition'</a> below.)</p><p class="headingAnchor" id="H2546402250"><span class="h3">Treatment of the underlying disease</span><span class="headingEndMark"> — </span>Treatment should be directed at the underlying disease. As an example, enzyme replacement therapy has been associated with alleviation of gastrointestinal manifestations in patients with Fabry disease. (See  <a class="medical medical_review" href="/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7207.html" rel="external">"Fabry disease: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H3285749738"><span class="h3">Symptomatic management</span><span class="headingEndMark"> — </span>Pharmacologic therapy is necessary for patients with severe symptoms or those who continue to have symptoms despite dietary modification. (See  <a class="medical medical_review" href="/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a>.)</p><p class="headingAnchor" id="H912585984"><span class="h4">Prokinetics</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="83328" href="/d/drug information/83328.html" rel="external">Prucalopride</a><strong> </strong>– 5HT4 receptor agonist, prucalopride, accelerates transit through the stomach, small bowel, and colon [<a href="#rid3">3</a>]. In a small randomized trial, prucalopride appeared to provide symptom relief in four of seven patients with CIPO [<a href="#rid4">4</a>]. In three patients with visceral myopathy and one with visceral neuropathy, 2 to 4 mg prucalopride (relative to placebo) significantly improved pain in three of four patients, nausea in two, vomiting in one, and bloating in four, whereas the frequency of bowel movements did not significantly change. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">Pyridostigmine</a><strong> </strong>–<strong> </strong>Pyridostigmine, an oral anticholinesterase, may be used in the chronic phase of CIPO. In small observational studies, pyridostigmine has demonstrated efficacy in the treatment of CIPO in adults and in children [<a href="#rid5">5,6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other prokinetic agents </strong>– We avoid the use of other prokinetics (eg, <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> and <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>) for management of chronic symptoms of CIPO due to their side effects and tachyphylaxis associated with erythromycin. </p><p></p><p class="headingAnchor" id="H173692650"><span class="h4">Antiemetic agents</span><span class="headingEndMark"> — </span>In patients with persistent symptoms despite the use of prokinetics, addition of an antiemetic medication may help to relieve symptoms of CIPO [<a href="#rid7">7</a>]. However, when coadministering antiemetics and prokinetics, it is important to consider potential metabolic drug interactions that may result in high blood levels resulting in drug toxicity. We treat patients with persistent symptoms despite prokinetics with an antiemetic medication (eg, <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a> 12.5 to 25 mg twice daily administered orally or as a rectal suppository or <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a>) for symptom relief. The sedative effects of promethazine may be helpful when administered at bedtime. In patients who cannot tolerate promethazine, a 5-HT3 antagonist (eg, oral <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> 4 to 8 mg three times daily) may be used. However, 5-HT3 antagonists can delay colonic transit. We therefore reserve their use in patients who cannot tolerate promethazine or prochlorperazine. (See  <a class="medical medical_review" href="/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a>.)</p><p class="headingAnchor" id="H3886342506"><span class="h2">Additional therapies in selected patients</span></p><p class="headingAnchor" id="H3755373304"><span class="h3">Patients with bacterial overgrowth</span><span class="headingEndMark"> — </span>Small intestinal bacterial overgrowth (SIBO) is suspected in patients with CIPO who have flatulence, chronic diarrhea, steatorrhea, and vitamin deficiencies (eg, fat-soluble vitamins and vitamin B12) that may not be absorbed normally. </p><p class="headingAnchor" id="H2356841149"><span class="h4">Antibiotics</span><span class="headingEndMark"> — </span>Patients with suspected SIBO should be treated empirically with antibiotics. Breath tests for SIBO are limited by large variations in their performance and interpretation in patients with severe dysmotility [<a href="#rid8">8</a>]. Jejunal aspirate cultures are needed if steatorrhea does not respond to empiric antibiotics. Jejunal aspirate culture is the preferred test for diagnosing SIBO in patients with CIPO as breath tests can have a high false-negative rate in patients with motility disorders [<a href="#rid9">9</a>]. The presence of ≥10<sup>5</sup> aerobic colony forming units/mL in the jejunal aspirate is consistent with SIBO. (See  <a class="medical medical_review" href="/d/html/4778.html" rel="external">"Small intestinal bacterial overgrowth: Management", section on 'Antibiotic therapy'</a> and  <a class="medical medical_review" href="/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p>In patients with severe myopathic disease with recurrent SIBO, antibiotic prophylaxis may be needed. (See  <a class="medical medical_review" href="/d/html/4778.html" rel="external">"Small intestinal bacterial overgrowth: Management", section on 'Antibiotic prophylaxis in selected patients'</a>.)</p><p class="headingAnchor" id="H52438553"><span class="h4">Octreotide</span><span class="headingEndMark"> — </span>We avoid the use of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> in patients with CIPO since it delays gastric emptying and small bowel transit of solids, which may be deleterious to patients with CIPO [<a href="#rid10">10,11</a>]. If it is to be used, it should only be administered before bedtime (at least two hours after the last meal). </p><p><a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> induces migrating motor complexes (MMCs), and limited evidence suggests that it may reduce the risk of bacterial overgrowth in patients with CIPO by moving food residue and possibly bacteria from the small intestine to the colon. In a series of five patients with scleroderma, octreotide (50 mcg administered subcutaneously at bedtime) caused an average of 3.6 MMCs in three hours of small bowel recordings when there had previously been none [<a href="#rid12">12</a>]. There was a significant reduction in breath hydrogen excretion as compared with baseline and a reduction in symptoms of nausea, bloating, and abdominal pain and emesis. A similar benefit to intestinal motility with improvement in symptoms was observed in a few patients with idiopathic intestinal pseudo-obstruction who were treated with octreotide in combination with <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> [<a href="#rid13">13</a>]. However, symptomatic improvement with octreotide may reflect changes in visceral afferent function rather than an effect upon transit through the intestine [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H2853835544"><span class="h3">Patients with paraneoplastic or inflammatory neuropathy</span><span class="headingEndMark"> — </span>Immunosuppressive therapy should be reserved for patients with CIPO due to an underlying inflammatory neuropathy that is established by biopsy and in patients with a paraneoplastic neuropathy by the presence of antineuronal antibodies (anti-Hu) [<a href="#rid16">16</a>]. In addition to treatment of the underlying tumor, immune therapy with glucocorticoids (<a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> starting at 40 to 60 mg daily) may be needed. <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> have also been used [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/5190.html" rel="external">"Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Autonomic neuropathy'</a>.)</p><p class="headingAnchor" id="H576244230"><span class="h2">Management of acute exacerbations</span><span class="headingEndMark"> — </span>Patients with acute exacerbations of CIPO are typically hospitalized and require intravenous fluids. Medications that can exacerbate CIPO should be discontinued (eg, opiates, calcium channel blockers, medications with anticholinergic side effects). If the patient has received mu-opiates, a peripherally acting mu opioid receptor antagonist such as subcutaneous <a class="drug drug_general" data-topicid="9444" href="/d/drug information/9444.html" rel="external">methylnaltrexone</a> (0.15 mg/kg) may improve symptoms. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Methylnaltrexone'</a>.)</p><p class="headingAnchor" id="H525913672"><span class="h3">Erythromycin</span><span class="headingEndMark"> — </span>We administer intravenous <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> lactobionate at a dose of 3 mg/kg every eight hours for at least five to seven days. Intravenous erythromycin is effective during acute exacerbations of CIPO, acting at least in part by stimulation of the motilin receptors [<a href="#rid18">18,19</a>]. In patients with systemic sclerosis (scleroderma) who have impaired gastric motility, erythromycin can improve gastric emptying [<a href="#rid20">20</a>]. However, we do not use erythromycin for chronic therapy as there is limited evidence to support its use and because of potential side effects [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/2639.html" rel="external">"Chronic intestinal pseudo-obstruction: Etiology, clinical manifestations, and diagnosis", section on 'Etiology'</a>.)</p><p class="headingAnchor" id="H679243897"><span class="h3">Anticholinesterases</span><span class="headingEndMark"> — </span>We reserve the use of anticholinesterases to patients with acute exacerbation of CIPO who fail to respond to <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>. Case reports have suggested that acute exacerbation of intestinal pseudo-obstruction may respond to treatment with <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> (0.5 mg intramuscular or intravenous over five minutes with cardiac monitoring) and its use relieved symptoms and was safe [<a href="#rid5">5,6</a>]. Neostigmine significantly increased antral and intestinal motor activity in patients with diverse upper gastrointestinal dysmotilities, including five patients with intestinal neuropathies or CIPO [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/2531.html" rel="external">"Acute colonic pseudo-obstruction (Ogilvie's syndrome)", section on 'Neostigmine'</a>.)</p><p class="headingAnchor" id="H3988638762"><span class="h3">Metoclopramide</span><span class="headingEndMark"> — </span>Intravenous <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> (10 mg up to four times daily) is an alternative in patients with an acute exacerbation of CIPO who cannot tolerate or fail to respond to both <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> and <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>. Side effects associated with metoclopramide include central side effects of anxiety, restlessness, and depression, hyperprolactinemia, QT interval prolongation and extrapyramidal side effects, including dystonia and tardive dyskinesia, which have led to a black box warning. A possible history of an extrapyramidal reaction to this agent should be elicited prior to beginning therapy. (See  <a class="medical medical_review" href="/d/html/2532.html" rel="external">"Treatment of gastroparesis", section on 'Metoclopramide'</a>.)</p><p class="headingAnchor" id="H6881430"><span class="h1">MANAGEMENT OF INTRACTABLE SYMPTOMS</span></p><p class="headingAnchor" id="H504175726"><span class="h2">Decompression and feeding</span><span class="headingEndMark"> — </span>Enteral nutrition is typically used for neuropathic disorders or in patients in whom the motility disorder is localized to the stomach and duodenum. Percutaneous endoscopic gastro-jejunostomy (PEG-J) decompression can provide an effective means for decompression and enteral nutrition [<a href="#rid23">23</a>]. Alternatively, access to the stomach or small bowel for venting (decompression to relieve symptoms) and feeding may be performed laparoscopically. Enteral feeding may thus facilitate avoidance of total parenteral nutrition-related complications, but is rarely tolerated by patients [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/2583.html" rel="external">"Enteral feeding: Gastric versus post-pyloric", section on 'Post-pyloric feeding'</a>.)</p><p>Colonoscopic insertion of a gastrostomy tube into the colon to relieve obstructive symptoms has been described in case reports. While the safety and long-term efficacy of this approach remain to be established, improvement in symptoms for up to two years has been reported [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H2801784539"><span class="h2">Parenteral nutrition</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">Parenteral nutrition</a> is necessary for patients with severe dysmotility (usually myopathic pseudo-obstruction) and in those who cannot tolerate enteral nutrition. In a large multicenter experience of home parenteral nutrition (HPN) for pediatric patients, the main complications were catheter-related bloodstream infections (1.7/1000 days of parenteral nutrition) and intestinal failure-associated liver disease (20 percent of cohort). Patients in the cohort with CIPO were not at greater risk than other indications [<a href="#rid26">26</a>]. However, patients with CIPO on total parenteral nutrition appear to have lower final heights and body weight Z-scores, and there may be micronutrient deficiencies transiently while receiving parenteral nutrition [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p class="headingAnchor" id="H3521722734"><span class="h2">Intestinal transplantation</span><span class="headingEndMark"> — </span>Intestinal transplantation is indicated in patients in whom long-term <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> cannot be initiated or continued safely due to complications or with a poor quality-of-life and worsening pain despite aggressive medical management and optimal parenteral nutrition [<a href="#rid28">28-30</a>]. </p><p>Limited experience suggests that adults with CIPO and irreversible total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> complications benefit from isolated intestinal transplant (associated with different surgical techniques to empty the native stomach) [<a href="#rid31">31</a>].</p><p>Long-term survival is achievable with better quality of life and low risk of disease recurrence. Graft rejection, graft-versus-host disease, and immunosuppression-related lymphoproliferative disorders are more common with small intestinal transplantation than after other organ transplants. However, the results of intestinal transplantation have improved over the past decade. </p><p>In a prospective study of 55 patients with CIPO (23 children and 32 adults) who underwent intestinal transplantation (43 without a concomitant liver transplant), patient survival at one and five years was 89 percent and 69 percent, respectively, with graft survival of 87 and 56 percent, respectively [<a href="#rid32">32</a>]. Retransplantation was successful in 86 percent. Initially restored nutritional autonomy was sustainable in 23 (70 percent) of 33 long-term survivors with improved quality of life. The remaining 10 recipients required reinstitution of HPN due to allograft enterectomy or gut dysfunction. Overall, this report concluded that long-term survival is achievable after intestinal transplantation, with better quality of life and low risk of disease recurrence. (See  <a class="medical medical_review" href="/d/html/4595.html" rel="external">"Overview of intestinal and multivisceral transplantation", section on 'Postoperative complications'</a>.)</p><p>Although autologous stem cell transplantation and liver transplantation have been used in patients with mitochondrial cytopathy, it is unclear if the benefits outweigh the risks [<a href="#rid33">33,34</a>]. </p><p>Autologously derived enteric neural stem cells (ENSC) are a possible treatment option for enteric neuropathies in the future. ENSC have been shown to functionally integrate and rescue function in animal models of intestinal disease. However, further studies are required to fully understand the mechanisms of ENSC rescue before this cellular therapy can be applied clinically [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/4595.html" rel="external">"Overview of intestinal and multivisceral transplantation"</a>.)</p><p class="headingAnchor" id="H1513869654"><span class="h2">Therapies without a clear role</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pacing of the intestine and electrical stimulation </strong>– Pacing of the intestine and electrical stimulation of the stomach or intestine are considered investigational at this time, although initial results have been favorable. (See  <a class="medical medical_review" href="/d/html/2578.html" rel="external">"Electrical stimulation for gastroparesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cannabinoids </strong>–<strong> </strong>Symptomatic relief has been reported in patients treated with <a class="drug drug_general" data-topicid="134930" href="/d/drug information/134930.html" rel="external">medical cannabis</a> [<a href="#rid36">36</a>]. However, it is important to note that, in general, nonselective cannabinoid receptor agonists generally inhibit gastrointestinal or colonic motility, and there are reports of intestinal intussusception with cannabis use [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fecal microbiota transplantation</strong> – A pilot study demonstrated safety of using serial frozen fecal microbiota transplantation, symptom relief (bloating, pain, and reduced intestinal dilatation on CT imaging) in selected patients with CIPO, and improvement in patient tolerance of enteral nutrition delivered via a naso-jejunal tube. Of note, four of the nine patients had previously undergone ileostomy [<a href="#rid38">38</a>]. Additional studies are needed to validate these findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resection of localized disease</strong> – In general, non-transplant surgical management of CIPO should be avoided, as it is associated with high postoperative morbidity and mortality rates and frequent re-operation [<a href="#rid39">39</a>]. Resection of localized disease should be avoided in patients with CIPO. Clinical experience suggests that even though the disease may appear to be localized, it usually becomes evident in the remaining bowel, thereby rendering the benefits of a bypass temporary. Repeated surgery also leads to diagnostic confusion, making it difficult to distinguish CIPO from small bowel obstruction. Subtotal enterectomy for pseudo-obstruction has been performed for relief of severe pain associated with markedly distended loops of intestine. In such cases, the patient is committed to total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> for life as a consequence of surgery. Bypass of dilated segments has been suggested for patients with megaduodenum. However, in our experience, this procedure has been ineffective in patients with persistent symptoms.</p><p></p><p class="headingAnchor" id="H3312663500"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>A number of clinical, histopathologic, and manometric features have been identified as being predictive of outcomes in patients with chronic intestinal pseudo-obstruction (CIPO)  (<a class="graphic graphic_table graphicRef86277" href="/d/graphic/86277.html" rel="external">table 1</a>) [<a href="#rid40">40,41</a>]. Long-term outcomes for patients with CIPO are especially poor in children, with 60 to 80 percent requiring <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> and a mortality rate ranging from 10 to 40 percent [<a href="#rid42">42-44</a>].</p><p>In adults with CIPO, the vast majority of patients have evidence of nutritional compromise, and almost one-third require long-term home <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> (HPN) [<a href="#rid40">40</a>]. Mortality rates of approximately 10 percent have been reported in adults, including HPN-related complications in 45 to 80 percent of cases [<a href="#rid45">45</a>]. In one series in adults that included 59 consecutive patients who were followed for a median of 4.6 years, symptoms associated with CIPO became progressively more severe with time [<a href="#rid46">46</a>]. Most patients had undergone a potentially dangerous surgery (mean 2.96 per patient) before a diagnosis was established, underscoring the need to recognize its presentation. Long-term outcomes were poor despite medical and surgical treatment. Approximately one-third of patients required long-term HPN, while about two-thirds had some nutritional limitation. Four patients underwent small bowel transplantation. Overall, 10 percent of patients died of disease-related complications.</p><p class="headingAnchor" id="H403733370"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116755.html" rel="external">"Society guideline links: Bowel obstruction"</a>.)</p><p class="headingAnchor" id="H3247061143"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>– Chronic intestinal pseudo-obstruction (CIPO) is a syndrome that suggests mechanical bowel obstruction of the small or large bowel in the absence of an anatomic lesion that obstructs the flow of intestinal contents. Segments of affected bowel appear dilated on radiography. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/2639.html" rel="external">"Chronic intestinal pseudo-obstruction: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management </strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial management of CIPO consists of dietary modification and treatment of the underlying disease. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with continued symptoms despite dietary modification or patients with severe symptoms, we suggest <a class="drug drug_general" data-topicid="83328" href="/d/drug information/83328.html" rel="external">prucalopride</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with persistent symptoms despite the use of prokinetics, addition of an antiemetic medication may help to relieve symptoms of CIPO. We prefer to use antiemetics such as <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a> and <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a> and reserve the use of 5HT3 antagonists (eg, <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>) for patients who cannot tolerate other antiemetic agents, as 5HT3 antagonists can delay colonic transit. (See <a class="local">'Initial management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with CIPO who have steatorrhea, fat-soluble vitamin or vitamin B12 malabsorption, we make a presumptive diagnosis of small intestinal bacterial overgrowth (SIBO) given the limitations of breath tests in patients with severe dysmotility. </p><p></p><p class="bulletIndent1">The management of SIBO in patients with CIPO is similar to other patients and consists of antibiotic therapy. Jejunal aspirate cultures are needed if steatorrhea does not respond to empiric antibiotics. </p><p></p><p class="bulletIndent1">We avoid the use of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> in patients with CIPO since it delays gastric emptying and small bowel transit of solids, which may be deleterious to patients with CIPO. (See <a class="local">'Additional therapies in selected patients'</a> above and  <a class="medical medical_review" href="/d/html/4778.html" rel="external">"Small intestinal bacterial overgrowth: Management", section on 'Antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of acute exacerbations</strong> – For symptomatic relief in patients with acute exacerbations of CIPO, we suggest intravenous <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> rather than other prokinetic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We reserve the use of intravenous anticholinesterases (eg, <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>) in patients with acute exacerbation of CIPO who fail to respond to erythromycin. (See <a class="local">'Management of acute exacerbations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with intractable symptoms</strong>  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgery should be performed to provide access to the stomach or small bowel for venting and feeding. Resection of localized disease should be avoided in patients with CIPO. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">Parenteral nutrition</a> is necessary for patients with severe dysmotility (usually myopathic pseudo-obstruction) and in those who cannot tolerate enteral nutrition. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intestinal transplantation is reserved for patients in whom long-term <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> cannot be initiated or continued safely. (See <a class="local">'Management of intractable symptoms'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vasant DH, Pironi L, Barbara G, et al. An international survey on clinicians' perspectives on the diagnosis and management of chronic intestinal pseudo-obstruction and enteric dysmotility. Neurogastroenterol Motil 2020; 32:e13937.</a></li><li><a class="nounderline abstract_t">Goulet O, Sauvat F, Jan D. Surgery for pediatric patients with chronic intestinal pseudo-obstruction syndrome. J Pediatr Gastroenterol Nutr 2005; 41 Suppl 1:S66.</a></li><li><a class="nounderline abstract_t">Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120:354.</a></li><li><a class="nounderline abstract_t">Emmanuel AV, Kamm MA, Roy AJ, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 2012; 35:48.</a></li><li><a class="nounderline abstract_t">Manini ML, Camilleri M, Grothe R, Di Lorenzo C. Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series. Paediatr Drugs 2018; 20:173.</a></li><li><a class="nounderline abstract_t">O'Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis 2010; 12:540.</a></li><li><a class="nounderline abstract_t">Abell TL, Camilleri M, DiMagno EP, et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36:616.</a></li><li><a class="nounderline abstract_t">Nightingale JMD, Paine P, McLaughlin J, et al. The management of adult patients with severe chronic small intestinal dysmotility. Gut 2020; 69:2074.</a></li><li><a class="nounderline abstract_t">Valdovinos MA, Camilleri M, Thomforde GM, Frie C. Reduced accuracy of 14C-D-xylose breath test for detecting bacterial overgrowth in gastrointestinal motility disorders. Scand J Gastroenterol 1993; 28:963.</a></li><li><a class="nounderline abstract_t">von der Ohe MR, Camilleri M, Thomforde GM, Klee GG. Differential regional effects of octreotide on human gastrointestinal motor function. Gut 1995; 36:743.</a></li><li><a class="nounderline abstract_t">Foxx-Orenstein A, Camilleri M, Stephens D, Burton D. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003; 52:1555.</a></li><li><a class="nounderline abstract_t">Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325:1461.</a></li><li><a class="nounderline abstract_t">Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 1995; 40:1892.</a></li><li><a class="nounderline abstract_t">Hasler WL, Soudah HC, Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 1993; 104:1390.</a></li><li><a class="nounderline abstract_t">Ambartsumyan L, Flores A, Nurko S, Rodriguez L. Utility of Octreotide in Advancing Enteral Feeds in Children with Chronic Intestinal Pseudo-Obstruction. Paediatr Drugs 2016; 18:387.</a></li><li><a class="nounderline abstract_t">De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil 2004; 16:515.</a></li><li><a class="nounderline abstract_t">Badari A, Farolino D, Nasser E, et al. A novel approach to paraneoplastic intestinal pseudo-obstruction. Support Care Cancer 2012; 20:425.</a></li><li><a class="nounderline abstract_t">Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992; 33:397.</a></li><li><a class="nounderline abstract_t">Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther 2004; 19:687.</a></li><li><a class="nounderline abstract_t">Fiorucci S, Distrutti E, Bassotti G, et al. Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastroenterol 1994; 29:807.</a></li><li><a class="nounderline abstract_t">Minami T, Nishibayashi H, Shinomura Y, Matsuzawa Y. Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol 1996; 31:855.</a></li><li><a class="nounderline abstract_t">Parthasarathy G, Ravi K, Camilleri M, et al. Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. Neurogastroenterol Motil 2015; 27:1736.</a></li><li><a class="nounderline abstract_t">Ohkubo H, Fuyuki A, Arimoto J, et al. Efficacy of percutaneous endoscopic gastro-jejunostomy (PEG-J) decompression therapy for patients with chronic intestinal pseudo-obstruction (CIPO). Neurogastroenterol Motil 2017; 29.</a></li><li><a class="nounderline abstract_t">Pakarinen MP, Kurvinen A, Koivusalo AI, et al. Surgical treatment and outcomes of severe pediatric intestinal motility disorders requiring parenteral nutrition. J Pediatr Surg 2013; 48:333.</a></li><li><a class="nounderline abstract_t">Thompson AR, Pearson T, Ellul J, Simson JN. Percutaneous endoscopic colostomy in patients with chronic intestinal pseudo-obstruction. Gastrointest Endosc 2004; 59:113.</a></li><li><a class="nounderline abstract_t">Abi Nader E, Lambe C, Talbotec C, et al. Outcome of home parenteral nutrition in 251 children over a 14-y period: report of a single center. Am J Clin Nutr 2016; 103:1327.</a></li><li><a class="nounderline abstract_t">Choi SJ, Lee KJ, Choi JS, et al. Poor Prognostic Factors in Patients with Parenteral Nutrition-Dependent Pediatric Intestinal Failure. Pediatr Gastroenterol Hepatol Nutr 2016; 19:44.</a></li><li><a class="nounderline abstract_t">Sigurdsson L, Reyes J, Kocoshis SA, et al. Intestinal transplantation in children with chronic intestinal pseudo-obstruction. Gut 1999; 45:570.</a></li><li><a class="nounderline abstract_t">Sauvat F, Fusaro F, Lacaille F, et al. Is intestinal transplantation the future of children with definitive intestinal insufficiency? Eur J Pediatr Surg 2008; 18:368.</a></li><li><a class="nounderline abstract_t">Ueno T, Wada M, Hoshino K, et al. A national survey of patients with intestinal motility disorders who are potential candidates for intestinal transplantation in Japan. Transplant Proc 2013; 45:2029.</a></li><li><a class="nounderline abstract_t">Lauro A, Zanfi C, Pellegrini S, et al. Isolated intestinal transplant for chronic intestinal pseudo-obstruction in adults: long-term outcome. Transplant Proc 2013; 45:3351.</a></li><li><a class="nounderline abstract_t">Sogawa H, Costa G, Armanyous S, et al. Twenty Years of Gut Transplantation for Chronic Intestinal Pseudo-obstruction: Technical Innovation, Long-term Outcome, Quality of Life, and Disease Recurrence. Ann Surg 2021; 273:325.</a></li><li><a class="nounderline abstract_t">Halter JP, Michael W, Schüpbach M, et al. Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain 2015; 138:2847.</a></li><li><a class="nounderline abstract_t">De Giorgio R, Pironi L, Rinaldi R, et al. Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Ann Neurol 2016; 80:448.</a></li><li><a class="nounderline abstract_t">McCann CJ, Thapar N. Enteric neural stem cell therapies for enteric neuropathies. Neurogastroenterol Motil 2018; 30:e13369.</a></li><li><a class="nounderline abstract_t">Zemrani B, Lambe C, Goulet O. Cannabinoids Improve Gastrointestinal Symptoms in a Parenteral Nutrition-Dependent Patient With Chronic Intestinal Pseudo-Obstruction. JPEN J Parenter Enteral Nutr 2021; 45:427.</a></li><li><a class="nounderline abstract_t">Prokopchuk O, Neumann PA, Hüser N, et al. Multiple intestinal intussusceptions caused by highly impaired gastrointestinal motility in a patient with chronic cannabis consumption. J Surg Case Rep 2019; 2019:rjz160.</a></li><li><a class="nounderline abstract_t">Gu L, Ding C, Tian H, et al. Serial Frozen Fecal Microbiota Transplantation in the Treatment of Chronic Intestinal Pseudo-obstruction: A Preliminary Study. J Neurogastroenterol Motil 2017; 23:289.</a></li><li><a class="nounderline abstract_t">Sabbagh C, Amiot A, Maggiori L, et al. Non-transplantation surgical approach for chronic intestinal pseudo-obstruction: analysis of 63 adult consecutive cases. Neurogastroenterol Motil 2013; 25:e680.</a></li><li><a class="nounderline abstract_t">Stanghellini V, Cogliandro RF, de Giorgio R, et al. Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil 2007; 19:440.</a></li><li><a class="nounderline abstract_t">Stanghellini V, Cogliandro RF, De Giorgio R, et al. Natural history of intestinal failure induced by chronic idiopathic intestinal pseudo-obstruction. Transplant Proc 2010; 42:15.</a></li><li><a class="nounderline abstract_t">Mousa H, Hyman PE, Cocjin J, et al. Long-term outcome of congenital intestinal pseudoobstruction. Dig Dis Sci 2002; 47:2298.</a></li><li><a class="nounderline abstract_t">Faure C, Goulet O, Ategbo S, et al. Chronic intestinal pseudoobstruction syndrome: clinical analysis, outcome, and prognosis in 105 children. French-Speaking Group of Pediatric Gastroenterology. Dig Dis Sci 1999; 44:953.</a></li><li><a class="nounderline abstract_t">Lu W, Xiao Y, Huang J, et al. Causes and prognosis of chronic intestinal pseudo-obstruction in 48 subjects: A 10-year retrospective case series. Medicine (Baltimore) 2018; 97:e12150.</a></li><li><a class="nounderline abstract_t">Mann SD, Debinski HS, Kamm MA. Clinical characteristics of chronic idiopathic intestinal pseudo-obstruction in adults. Gut 1997; 41:675.</a></li><li><a class="nounderline abstract_t">Stanghellini V, Cogliandro RF, De Giorgio R, et al. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol 2005; 3:449.</a></li></ol></div><div id="topicVersionRevision">Topic 132410 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32696607" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : An international survey on clinicians' perspectives on the diagnosis and management of chronic intestinal pseudo-obstruction and enteric dysmotility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131977" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Surgery for pediatric patients with chronic intestinal pseudo-obstruction syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159875" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22061077" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29243034" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508545" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022163" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32826308" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The management of adult patients with severe chronic small intestinal dysmotility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8284631" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reduced accuracy of 14C-D-xylose breath test for detecting bacterial overgrowth in gastrointestinal motility disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797125" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Differential regional effects of octreotide on human gastrointestinal motor function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14570722" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944424" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555439" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8097733" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27520652" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Utility of Octreotide in Advancing Enteral Feeds in Children with Chronic Intestinal Pseudo-Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15500508" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Human enteric neuropathies: morphology and molecular pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22072051" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A novel approach to paraneoplastic intestinal pseudo-obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1568663" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Erythromycin and the gut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023171" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7824860" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9027652" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26387781" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28631871" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy of percutaneous endoscopic gastro-jejunostomy (PEG-J) decompression therapy for patients with chronic intestinal pseudo-obstruction (CIPO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414861" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Surgical treatment and outcomes of severe pediatric intestinal motility disorders requiring parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722563" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Percutaneous endoscopic colostomy in patients with chronic intestinal pseudo-obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27030532" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Outcome of home parenteral nutrition in 251 children over a 14-y period: report of a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27066448" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Poor Prognostic Factors in Patients with Parenteral Nutrition-Dependent Pediatric Intestinal Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10486367" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Intestinal transplantation in children with chronic intestinal pseudo-obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19023853" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Is intestinal transplantation the future of children with definitive intestinal insufficiency?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23769101" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A national survey of patients with intestinal motility disorders who are potential candidates for intestinal transplantation in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24182815" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Isolated intestinal transplant for chronic intestinal pseudo-obstruction in adults: long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31274659" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Twenty Years of Gut Transplantation for Chronic Intestinal Pseudo-obstruction: Technical Innovation, Long-term Outcome, Quality of Life, and Disease Recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26264513" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27421916" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29707856" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Enteric neural stem cell therapies for enteric neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32181915" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cannabinoids Improve Gastrointestinal Symptoms in a Parenteral Nutrition-Dependent Patient With Chronic Intestinal Pseudo-Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31139341" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Multiple intestinal intussusceptions caused by highly impaired gastrointestinal motility in a patient with chronic cannabis consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27840368" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Serial Frozen Fecal Microbiota Transplantation in the Treatment of Chronic Intestinal Pseudo-obstruction: A Preliminary Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23895212" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Non-transplantation surgical approach for chronic intestinal pseudo-obstruction: analysis of 63 adult consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17564625" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chronic intestinal pseudo-obstruction: manifestations, natural history and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20172271" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Natural history of intestinal failure induced by chronic idiopathic intestinal pseudo-obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12395903" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term outcome of congenital intestinal pseudoobstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235603" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Chronic intestinal pseudoobstruction syndrome: clinical analysis, outcome, and prognosis in 105 children. French-Speaking Group of Pediatric Gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30200110" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Causes and prognosis of chronic intestinal pseudo-obstruction in 48 subjects: A 10-year retrospective case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9414977" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical characteristics of chronic idiopathic intestinal pseudo-obstruction in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15880314" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
